FDA Oncology Announcements

BTK inhibitor × Other × Clear all

2 Announcements

FDA approves ibrutinib for pediatric patients with chronic graft versus host disease, including a new oral suspension

Drug: Imbruvica (ibrutinib) · BTK inhibitor
Condition: Other

FDA expands ibrutinib indications to chronic GVHD

Drug: Imbruvica (ibrutinib) · BTK inhibitor
Condition: Other